The closing removes completion risk and solidifies the balance sheet. With extended runway into Q2 2028, the company has increased financial flexibility to execute on its cardiovascular gene therapy pipeline. Monitor for upcoming clinical catalysts and potential business development activities enabled by this liquidity.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $2.75entry
- T+1 · 5mo ago +4.00%α +2.24% · $2.86
- T+5 · 5mo ago +21.82%α +21.15% · $3.35
- T+20 · 4mo ago +42.18%α +40.40% · $3.91
- T+60 · 2mo ago +34.91%α +31.65% · $3.71
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million in gross proceeds, a previously announced transaction. The non-dilutive capital infusion boosts pro-forma cash to approximately $322.6 million and extends the company's cash runway into the second quarter of 2028, strengthening its balance sheet as it advances its cardiovascular gene therapy pipeline.
Key Facts
- Completed sale of PRV for $180.0 million in gross proceeds
- Pro-forma cash, cash equivalents and investments increased to approximately $322.6 million
- Cash runway extended into Q2 2028
- Transaction closed on June 10, 2026, announced via press release on June 12, 2026
- PRV was originally granted by the FDA in March 2026 in connection with KRESLADI approval
Financial Impact
Gross proceeds of $180.0 million added; pre-sale cash was $144.4 million, post-sale pro forma cash ~$322.6 million
Risk Factors
- Pipeline execution and clinical trial risks remain
- Stock may have already priced in the PRV sale from the prior announcement
- One-time monetization event without recurring revenue impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-024997 |
| Document: ef20076119_ex99-1.htm | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index-headers.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997-index.html | 0001140361-26-024997 |
| Document: 0001140361-26-024997.txt | 0001140361-26-024997 |
Track record
21 reports on RCKT
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +37.71% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers